Thompson C, Salvato P, Stroud S, Hasheeve DV; National Conference on Human Retroviruses and Related Infections.
Program Abstr First Natl Conf Hum Retrovir Relat Infect Natl Conf Hum Retrovir Relat Infect 1st 1993 Wash DC. 1993 Dec 12-16; 130.
Houston Immunological Institute, Houston, TX.
Objective: To determine if P24 antigenaemia conversion was different in patients receiving AZT versus AZT/Acyclovir. Methods: Sample consisted of 68 HIV seropositive subjects who were participating in the 3rd year of a longitudinal study of HIV disease markers. Peripheral blood was drawn at year 2 and analyzed for P24 antigen. 26 subjects were P24 negative at that drawing. A drug history was obtained from each of these 26. Four subjects were receiving no medication (approximately x CD4 590), 5 were on AZT alone (approximately x CD4 154), 4 were on Acyclovir alone (approximately x CD4 840), 13 were on combination AZT/Acyclovir (approximately x CD4 166). Chi square was used to test the association between P24 conversion and medication type. P24 antigen was again drawn at year 3. Results: 3 of the 26 subjects converted to P24 positive status over the 12-month period. Chi square results indicated significance at p greater than .003. 60% of those subjects on AZT alone converted to P24 positive while 0% conversion occurred for those receiving no medication, Acyclovir alone, or AZT/Acyclovir combination therapy. Conclusion: P24 antigenaemia most often occurs shortly following HIV seroconversion and again in the late stages of AIDS. It is not surprising therefore that patients who had high CD4 counts were either on no medication or Acyclovir alone did not convert to P24 positive. All 13 patients on combination AZT/Acyclovir remained P24 negative while 3 out of 5 on AZT alone converted to positive. However, both the AZT only group and the AZT/Acyclovir group had similar low CD4 counts (less than 200) but only the AZT monotherapy group demonstrated conversion. Data from this study suggests that combination AZT/Acyclovir therapy may delay P24 antigenaemia as compared to AZT alone. Further study is need on AZT/Acyclovir combination therapy.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Acyclovir
- Antigens
- Antigens, CD4
- CD4 Lymphocyte Count
- HIV
- HIV Antibodies
- HIV Antigens
- HIV Core Protein p24
- HIV Infections
- HIV Seropositivity
- Humans
- Immunologic Techniques
- Longitudinal Studies
- Zidovudine
- immunology
- organization & administration
Other ID:
UI: 102214378
From Meeting Abstracts